Effects of caffeine on blood flow in glaucoma patients and healthy individuals
Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow After Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optic Coherence Tomography Angiography (OCTA) Study
This study tests how drinking caffeine affects blood flow in the eyes of people with glaucoma and healthy individuals.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Wills Eye Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT03675412 on ClinicalTrials.gov |
What this trial studies
This study investigates how caffeine consumption affects blood flow in the eyes of glaucoma patients and healthy subjects. Participants will ingest a 200 milligram caffeine tablet, and their peripapillary and macular blood flow will be assessed using optical coherence tomography angiography (OCTA) scans before and after caffeine intake. The study aims to understand the acute changes in blood flow, which may have implications for glaucoma management. By utilizing a non-invasive imaging technique, researchers hope to gather valuable data on the vascular effects of caffeine.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 90 with a diagnosis of primary open angle glaucoma or healthy individuals without eye disease.
Not a fit: Patients with significant ocular or systemic diseases that could affect OCTA results or those with certain eye conditions will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how caffeine affects ocular blood flow, potentially influencing treatment strategies for glaucoma.
How similar studies have performed: While caffeine's effects on ocular blood flow have been studied, this specific approach using OCTA in glaucoma patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 18 to 90 years * diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced) * healthy subjects with no eye disease Exclusion Criteria: * Diseases, ophthalmic or systemic, that are likely to affect OCTA results * greater than moderate cataract * nystagmus * inability to look at target * macular degeneration other than mild drusen or pigmentary changes * diabetic retinopathy * neovascular glaucoma or non-glaucoma optic neuropathies * current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy * keratoconus, corneal ectasia, central corneal scarring * rheumatologic diseases or Raynaud's phenomena * pregnant and lactating women * mental illness or alcohol addiction * pre-existing bladder symptoms, cardiac disease or sleep disorder * refractive spherical diopter greater than 5 or cylinder greater than 3 * possible tolerance to caffeine (drinking more than 1 cup coffee per day).
Where this trial is running
Philadelphia, Pennsylvania
- Wills Eye Glaucoma Service — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: M. Reza Razeghinejad, MD — Wills Eye Hospital
- Study coordinator: M. Reza Razeghinejad, MD
- Email: mrazeghi@willseye.org
- Phone: 215-928-7023
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.